The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study

American Journal of Obstetrics and Gynecology

Volumn 215, Issue 2, 2016, Pages 237.e1-237.e6

  Naidu, Madison A ^a   Muljadi, Ruth ^b   Davies Tuck, Miranda L ^a,b   Wallace, Euan M ^a,b,c   Giles, Michelle L ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c SOUTHERN HEALTH   (Australia)

Author keywords

Bordetella pertussis; maternal vaccination; newborn; pertussis vaccine

Indexed keywords

BACTERIUM ANTIBODY; FILAMENTOUS HEMAGGLUTININ ANTIBODY; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; PERTACTIN ANTIBODY; PERTUSSIS TOXIN ANTIBODY; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; ADHESIN; BORDETELLA VIRULENCE FACTOR; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; OUTER MEMBRANE PROTEIN; PERTACTIN; PERTUSSIS TOXIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; MATERNAL AGE; MATERNAL SERUM; PERTUSSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VACCINATION; VENOUS BLOOD; FETUS BLOOD; IMMUNOLOGY; PREGNANCY; PROCEDURES; WHOOPING COUGH;

ADHESINS, BACTERIAL; ADULT; BACTERIAL OUTER MEMBRANE PROTEINS; FEMALE; FETAL BLOOD; HUMANS; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; VACCINATION; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 84964380842     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.03.002     Document Type: Article

References (30)

1. 1 Paddock, C.D., Sanden, G.N., Cherry, J.D., et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 47 (2008), 328–338.
2. 2 De Melker, H.E., Schellekens, J.F., Neppelenbroek, S.E., Mooi, F.R., Rümke, H.C., Conyn-van Spaendonck, M.A., Reemergence of pertussis in the highly vaccinated population of The Netherlands: observations on surveillance data. Emerg Infect Dis 6 (2000), 348–357.
3. 3 Celentano, L.P., Massari, M., Paramatti, D., Salmaso, S., Tozzi, A.E., EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24 (2005), 761–765.
4. 4 Cherry, J.D., Epidemic pertussis in 2012–the resurgence of a vaccine-preventable disease. N Engl J Med 367 (2012), 785–787.
5. 5 Vitek, C.R., Pascual, F.B., Baughman, A.L., Murphy, T.V., Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 22 (2003), 628–634.
6. 6 Heininger, U., Riffelmann, M., Bär, G., Rudin, C., von König, C.-H.W., The protective role of maternally derived antibodies against Bordetella pertussis in young infants. Pediatr Infect Dis J 32 (2013), 695–698.
7. 7 Healy, C.M., Munoz, F.M., Rench, M.A., Halasa, N.B., Edwards, K.M., Baker, C.J., Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 190 (2004), 335–340.
8. 8 Englund, J.A., Anderson, E.L., Reed, G.F., et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96 (1995), 580–584.
9. 9 Wendelboe, A.M., Njamkepo, E., Bourillon, A., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26 (2007), 293–299.
10. 10 Munoz, F.M., Bond, N.H., Maccato, M., et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA, 311, 2014, 1760.
11. 11 Donegan, K., King, B., Bryan, P., Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ, 349, 2014, g4219.
12. 12 Zheteyeva, Y.A., Moro, P.L., Tepper, N.K., et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 207 (2012), 59.e1–59.e7.
13. 13 Saji, F., Samejima, Y., Kamiura, S., Koyama, M., Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod 4 (1999), 81–89.
14. 14 Simister, N.E., Placental transport of immunoglobulin G. Vaccine 21 (2003), 3365–3369.
15. 15 Van Savage, J., Decker, M.D., Edwards, K.M., Sell, S.H., Karzon, D.T., Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 161 (1990), 487–492.
16. 16 Edwards, K.M., Pertussis: an important target for maternal immunization. Vaccine 21 (2003), 3483–3486.
17. 17 Amirthalingam, G., Andrews, N., Campbell, H., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384 (2014), 1521–1528.
18. 18 Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60 (2011), 1424–1426.
19. 19 Davies S; Department of Health. Whooping cough vaccination program for pregnant women. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/212947/CMO-Pertussis-27-09-2012-FINAL.pdf. Accessed October 19, 2015.
20. 20 Healy, C.M., Rench, M.A., Baker, C.J., Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 56 (2013), 539–544.
21. 21 Gall, S.A., Myers, J., Pichichero, M., Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 204 (2011), 334.e1–334.e5.
22. 22 Hardy-Fairbanks, A.J., Pan, S.J., Decker, M.D., et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J 32 (2013), 1257–1260.
23. 23 Abu Raya, B., Srugo, I., Kessel, A., et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels–a prospective study. Vaccine 32 (2014), 5787–5793.
24. 24 Leuridan, E., Hens, N., Peeters, N., de Witte, L., Van der Meeren, O., Van Damme, P., Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 30 (2011), 608–610.
25. 25 Storsaeter, J., Hallander, H.O., Gustafsson, L., Olin, P., Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 (1998), 1907–1916.
26. 26 Taranger, J., Trollfors, B., Lagergård, T., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 (2000), 1010–1013.
27. 27 National Institute for Health and Excellence 2008. Antenatal care (NICE clinical guideline 62). Available at: guidance.nice.org.uk/cg62. Accessed October 19, 2015.
28. 28 Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden–protective efficacy and adverse events. Lancet 1 (1988), 955–960.
29. 29 Trollfors, B., Taranger, J., Lagergård, T., et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 333 (1995), 1045–1050.
30. 30 Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunization handbook, 10th ed., 2013, Australian Government Department of Health, Canberra.